Better oncology drug management could lead to improved outcomes, lower costs

In The Headlines: How tariffs could cause direct harm to patients

In this episode of the Cancer Letter Podcast, all three of The Cancer Letter’s reporters come together to talk about the potential impact of President Donald Trump’s tariffs on cancer care.

March 26, 2025

Vol.51 No.11

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Scripius and Avera collaborate to reduce prescription costs

Scripius, a Utah-based Pharmacy Benefit Management, or PBM, service, and Avera formed a collaboration aimed at reducing prescription costs. Scripius will serve as the PBM for approximately 80,000 Avera Health Plans members.

April 05, 2024

Vol.50 No.14

Guest Editorial

Turning the page: Projections for cancer care in the coming year

As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers.

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

A confirmation hearing for NCI Director Monica Bertagnolli will take place sometime in October, said Sen. Bernie Sanders (I-VT), chairman of the Senate Health, Education, Labor, and Pensions Committee.

September 15, 2023

Vol.49 No.34

By Matthew Bin Han Ong

Better oncology drug management could lead to improved outcomes, lower costs

YOU MAY BE INTERESTED IN

In The Headlines: How tariffs could cause direct harm to patients

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Scripius and Avera collaborate to reduce prescription costs

Turning the page: Projections for cancer care in the coming year

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

Renew today!

Subscriber content

Better oncology drug management could lead to improved outcomes, lower costs

YOU MAY BE INTERESTED IN

In The Headlines: How tariffs could cause direct harm to patients

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Scripius and Avera collaborate to reduce prescription costs

Turning the page: Projections for cancer care in the coming year

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

Obstacles cleared for Bertagnolli’s confirmation as NIH directorSenate HELP Committee schedules hearing

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing